Top Medical News
Pearl Toh, 7 hours ago
Young, healthy individuals at low risk for atherosclerotic cardiovascular disease (ASCVD) events may still face a heightened lifetime risk of death from CV events if they have elevated LDL-C levels of ≥160 mg/dL, reveal the CCLS*.
8 hours ago
Mirabegron, a β3-adrenoreceptor agonist, poses no increased cardiovascular risk when used as treatment for overactive bladder syndrome, a new study has found.
Roshini Claire Anthony, 12 hours ago

The combination of brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A+CHP) more than doubled progression-free survival (PFS) as well as improved overall survival (OS) in patients with CD30-expressing peripheral T-cell lymphoma compared with a combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), according to results of the phase III ECHELON-2* trial.

12 hours ago
Intensive statin therapy in the secondary prevention of ischaemic stroke or transient ischaemic attack significantly increases the risk of premature discontinuation as compared with a moderate intensity, a study has found.
15 hours ago
A direct switch to indacaterol/glycopyrronium (IND/GLY) from salmeterol/fluticasone (SFC) in chronic obstructive pulmonary disease (COPD) patients with up to one exacerbation in the previous year improves predose forced expiratory volume in 1 s (FEV1) and forced vital capacity without presenting new safety signals, a recent study has found.
Jairia Dela Cruz, 15 hours ago
The use of the PARP inhibitor olaparib in the maintenance setting confers notable gains in progression-free survival in women with newly diagnosed advanced ovarian cancer and a BRCA1/2 mutation, according to data from the phase III SOLO1 trial.
20 hours ago
Elevated lipoprotein(a) [Lp(a)] carries an increased risk of cardiovascular (CV) events in patients with established CV disease independent of low-density lipoprotein cholesterol, according to a study. PCSK9 inhibition with evolocumab reduces Lp(a) levels, and the cardioprotective effect is pronounced in patients with higher Lp(a) levels at baseline.
Special Reports
01 Nov 2018
The prevalence of allergic diseases in the Asia-Pacific region is expected to rise over the next 20 years, driven by rapid economic development and urbanization. Allergic diseases have high socioeconomic impact by impairing productivity and quality of life, and the impact may be greater in Asia-Pacific than in Europe due to the presence and predominance of perennial allergens.
Dr. Robert Giugliano, Prof. Ulrich Laufs, Prof. Gaetano De Ferrari, Prof. Naveed Sattar, 11 Oct 2018

The FOURIER trial previously demonstrated that adding the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab to background statin therapy lowered LDL-cholesterol (LDL-C) below target levels and significantly reduced the risks of cardiovascular (CV) events in patients with atherosclerotic cardiovascular disease (ASCVD). At the European Society of Cardiology (ESC) Congress 2018 in Munich, Germany, experts reiterated how evolocumab helps lower LDL-C levels and reduces CV events even in patients with various comorbidities.

27 Sep 2018
PRALUENT – alirocumab 75 mg/mL and 150 mg/mL soln for inj - sanofi-aventis
27 Sep 2018
VICTOZA – Liraglutide 6 mg/mL soln for inj - Novo Nordisk
27 Sep 2018
SKYCELLFLU – Inactivated quadrivalent influenza vaccine (inj) 0.5 mL - AJ Biologics
Rachel Soon, 01 Sep 2018

MIMS Pharmacist presents an overview of a standardized extract of Pinus pinaster bark, and its potential role in slowing down the progression of diabetic retinopathy.

Rachel Soon, 25 Jul 2018

MIMS Pharmacist presents an overview of Lactobacillus plantarum 299v's physiological role, as well as contemporary research on its pharmacology and effects.

Conference Reports
Elaine Soliven, 10 Dec 2018
Treatment with luspatercept, a first-in-class erythroid maturation agent, significantly achieves red blood cell transfusion independence (RBC-TI) in patients with anaemia who had low-risk myelodysplastic syndrome (MDS) with ring sideroblasts (RS), according to results of the MEDALIST* trial presented at ASH 2018.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
Roshini Claire Anthony, 07 Dec 2018

Findings from the updated analysis of the phase III MURANO* trial solidify the role of fixed-dose venetoclax plus rituximab in a majority of patients with relapsed/refractory chronic lymphocytic leukaemia (CLL).

Elvira Manzano, 07 Dec 2018
Systemic administration of the gene therapy scAAV2/8-LP1-hFIXco to patients with severe haemophilia B led to stable therapeutic expression of the factor IX gene over 8 years without evidence of late toxicities from treatment, according to a long-term follow-up study.
Elvira Manzano, 05 Dec 2018
Apalutamide, added to standard treatment with androgen deprivation therapy (ADT), provides comparable clinical benefits among Asian vs non-Asian patients with nonmetastatic castration-resistant prostate cancer (nmCRPC), according to a subset analysis of the phase III SPARTAN study.
Elaine Soliven, 05 Dec 2018

Treatment with ramucirumab, a human IgG1 monoclonal antibody, significantly improves overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) in both Asians and non-Asians, based on a pooled analysis of REACH* and REACH-2** studies presented at ESMO Asia 2018.

Jairia Dela Cruz, 05 Dec 2018
Beta blockers and/or renin-angiotensin inhibitors appear to be useful for preventing cardiotoxicity from anthracycline exposure, according to the results of a systematic review and meta-analysis presented at the European Society for Medical Oncology (ESMO) Asia 2018 Congress.
CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download